Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15311720 | 0.98 | NOTUM (0.40) | NOTUMPNMTKDM1APARP1NISCH | |
| SCHEMBL20571510 | 0.89 | KDM1A (0.41) | NOTUMPNMTKDM1ANISCHTSHR | |
| SCHEMBL30479618 | 0.89 | KDM1A (0.41) | NOTUMPNMTKDM1ANISCHTSHR | |
| Hydrochloric Acid SCHEMBL31477155 | 0.87 | KDM1A (0.41) | NOTUMPNMTKDM1ANISCHTSHR | |
| SCHEMBL28228556 | 0.82 | NOTUM (0.40) | NOTUMKDM1APARP1HTT | |
| SCHEMBL5754293 | 0.80 | PNMT (0.55) | NOTUMPNMTKDM1APARP1NISCH | |
| SCHEMBL27880380 | 0.76 | PNMT (0.39) | PNMTNISCHHTR2CHTR2BTSHR | |
| SCHEMBL31477384 | 0.76 | PNMT (0.39) | PNMTNISCHHTR2CHTR2BTSHR | |
| SCHEMBL175017 | 0.75 | GAA (0.56) | TSHR | |
| SCHEMBL26923247 | 0.74 | PARP1 (0.38) | NOTUMKDM1APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311874-A | The bicyclic heterocyclic compounds being substituted | 百时美施贵宝公司 | 2019-02-05 | — | — | CN | claimed |
| WO-2024084394-A1 | COMPOSITIONS AND METHODS FOR DELIVERING A MACROMOLECULE TO A CELL | ASTRAZENECA AB (SE) | 2024-04-25 | — | — | WO | disclosed |
| CN-117886810-A | Indoline compound and preparation method and application thereof | 徐州医科大学 | 2024-04-16 | — | — | CN | disclosed |
| CN-109843289-B | Diaryl sulfur group compound for resisting candida albicans, preparation and application thereof | 华南农业大学 | 2021-10-29 | — | — | CN | disclosed |
| CN-109843289-A | A kind of diaryl chalcogenide of anti-candida albicans and its preparation and application | 华南农业大学 | 2019-06-04 | — | — | CN | disclosed |
| EP-2658844-B1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-2590942-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-04 | — | — | EP | disclosed |
| EP-2590942-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-04 | — | — | EP | disclosed |
| US-9079880-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-9079880-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| CN-101119968-A | Heterocyclically substituted phenyl methanone derivatives as glycine transporter 1 inhibitors | HOFFMANN LA ROCHE (CH) | 2008-02-06 | — | — | CN | disclosed |
| EP-1848694-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F. Hoffmann-Roche AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006082001-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006082001-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | CYP2B6, CYP2D6, CYP1A2 | NOTUM 2424/4885PNMT 1672/4885KDM1A 1782/4885 |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | CYP2B6, CYP2D6, CYP1A2 | NOTUM 2424/4885PNMT 1672/4885KDM1A 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.